An interventional study of duostim vs. two antagonist ovarian stimulations in Infertility, sponsored by Shanghai First Maternity and Infant Hospital. Not yet recruiting. Open to female participants aged 20 Years to 44 Years. Per ClinicalTrials.gov, last updated 2023-10-23.
Sponsored by Shanghai First Maternity and Infant Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To compare the difference in cumulative live birth rates between dual ovarian stimulation and two antagonist stimulations in poor ovarian responders.
Studies have shown the ability to obtain oocytes with equivalent quality from the follicular and the luteal phase, and a higher number of oocytes within one cycle when using dual ovarian stimulation (duostim). This could be particularly relevant for women with poor ovarian responders (POR). Whether the cumulative live birth rates differ after duostim and two antagonist stimulations in POR remains controversial.
2,090 studies on the registry are indexed under Infertility; 355 are open to participants now.
This study's planned enrollment of 260 is above the median of 133 across 1,415 interventional studies indexed under Infertility.
Browse Infertility studies →Shanghai First Maternity and Infant Hospital is the lead sponsor of 48 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dual stimulations were performed during the follicular and luteal phases in the same cycle.
Procedure: duostim vs. two antagonist ovarian stimulations
Antagonist stimulations were performed during two consecutive follicular phases in two cycles.
Procedure: duostim vs. two antagonist ovarian stimulations
Human menopausal gonadotropin (HMG) 300 IU/day with flexible antagonist protocol is used for ovarian stimulation, except in luteal phase stimulation of the duostim group. In the duostim group, all of the embryos are frozen. Fresh transfers are performed in the control group, frozen embryo transfers are performed in both control and duostim groups.
Cumulative live birth rate
Live birth is defined as the delivery of any alive infant after 22 weeks of gestation after our interventions, and cumulative live birth rate is calculated by the total number of women randomized to the specific group.
Time frame: 36 months
Time to live birth (TTLB)
The TTLB was measured as the time from ovarian stimulation to a live birth.
Time frame: 36 months
Total amount of Gn used during ovarian stimulation
Total amount of Gn used during ovarian stimulation
Time frame: 24 months
Number of retrieved oocytes
Number of retrieved oocytes after ovarian stimulation.
Time frame: 24 months
Clinical pregnancy rate
Twenty days after conception, transvaginal ultrasonography will be performed. Clinical pregnancy will be diagnosed with detection of an intrauterine gestational sac.
Time frame: 36 months
No study locations are listed for this record.
Start is estimated for Nov 2023; primary completion for Oct 2025, 23 months later.
Of 385 non-industry interventional studies with no phase under Infertility, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 23 months is close to that.
Counting every sponsor, half of 415 studies reached it within 24 months; a quarter within 10 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai First Maternity and Infant Hospital